Survey on cannabis use in Parkinson's disease: Subjective improvement of motor symptoms

Movement Disorders

Volumn 19, Issue 9, 2004, Pages 1102-1106

  Venderová, Kateřina ^a   Ružička, Evžen ^b   Vorřísšek, Viktor ^c   Višňovský, Peter ^a  

^a Charles University in Prague Faculty of Pharmacy   (Czech Republic)

^b CHARLES UNIVERSITY   (Czech Republic)

^c UNIVERSITY HOSPITAL HRADEC KRALOVE   (Czech Republic)

Author keywords

Cannabinoid; Cannabis; Parkinson's disease

Indexed keywords

ANTIPARKINSON AGENT; CANNABIS; LEVODOPA;

ADULT; AGED; ARTICLE; BRADYKINESIA; CONTROLLED STUDY; CZECH REPUBLIC; DRUG BLOOD LEVEL; DRUG USE; DYSKINESIA; FEMALE; GAS CHROMATOGRAPHY; HEALTH CARE FACILITY; HEALTH SURVEY; HUMAN; MAJOR CLINICAL STUDY; MALE; MASS SPECTROMETRY; MOTOR DYSFUNCTION; MUSCLE RIGIDITY; PARKINSON DISEASE; PRIORITY JOURNAL; QUESTIONNAIRE; SYMPTOM; TREATMENT OUTCOME; TREMOR;

ADULT; AGED; AGED, 80 AND OVER; CANNABINOIDS; FEMALE; HUMANS; MALE; MARIJUANA ABUSE; MIDDLE AGED; PARKINSON DISEASE; PREVALENCE; QUESTIONNAIRES; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 4644341666     PISSN: 08853185     EISSN: None     Source Type: Journal    
DOI: 10.1002/mds.20111     Document Type: Article

References (32)

1. Izzo AA, Fezza F, Capasso R, et al. Cannabinoid CB1-receptor mediated regulation of gastrointestinal motility in mice in a model of intestinal inflammation. Br J Pharmacol 2001;134:563-570.
2. Bisogno T, Sepe N, Melck D, Maurelli S, De Petrocellis L, Di Marzo V. Biosynthesis, release and degradation of the novel endogenous cannabimimetic metabolite 2-arachidonoyl glycerol in mouse neuroblastoma cells. Biochem J 1997;322:671-677.
3. Fride E, Mechoulam R. Pharmacological activity of the cannabinoid receptor agonist, anandamide, a brain constituent. Eur J Pharmacol 1993;231:313-314.
4. Muller-Vahl KR, Kolbe H, Schneider U, Emrich HM. Cannabis in movement disorders. Forsch Komplementarmed 1999;3(Suppl.): 23-27.
5. Sanudo-Pena MC, Tsou KJ, Walker JM. Motor actions of cannabinoids in the basal ganglia output nuclei. Life Sci 1999;65:703-713.
6. Tsou K, Brown S, Sanudo-Pena MC, Mackie K, Walker JM. Immunohistochemical distribution of cannabinoid CB1 receptor in the rat central nervous system. Neuroscience 1998;83:393-411.
7. Di Matzo V, Hill MP, Bisogno T, Crossman AR, Brotchie JM. Enhanced levels of endogenous cannabinoids in the globus pallidus are associated with a reduction in movement in an animal model of Parkinson's disease. FASEB J 2000;14:1432-1438.
8. Zimmer A, Zimmer AM, Hohmann AG, Herkenham M, Bonner TI. Increased mortality, hypoactivity, and hypoalgesia in cannabinoid CB1 receptor knockout mice. Proc Natl Acad Sci USA 1999;96:5780-5785.
9. Steiner H, Bonner TI, Zimmer AM, Kitai ST, Zimmer A. Altered gene expression in striatal projection neurons in CB1 cannabinoid receptor knockout mice. Proc Natl Acad Sci U S A 1999;96:5786-5790.
10. Růžička E. Chewing marijuana induced improvement in Parkinson's disease. Parkinsonism Relat Disord 1999;5:85
11. Consroe P, Musty R, Rein J, Tillery W, Pertwee R. Perceived effects of cannabis smoking on patients with multiple sclerosis. Eur Neurol 1997;38:44-48.
12. Gubellini P, Picconi B, Bari M, et al. Experimental parkinsonism alters endocannabinoid degradation: implications for striatal glutamatergic transmission. J Neurosci 2002;22:6900-6907.
13. Silverdale MA, McGuire S, McInnes A, Crossman AR, Brotchie JM. Striatal cannabinoid CB1 receptor mRNA expression is decreased in the reserpine-treated rat model of Parkinson's disease. Exp Neurol 2001;169:400-406.
14. Romero J, Berrendero F, et al. Unilateral 6-hydroxydopamine lesions of nigrostriatal dopaminergic neurons increased CB1 receptor mRNA levels in the caudate-putamen. Life Sci 1999;66: 485-494.
15. Lastres-Becker I, Cebeira M, de Ceballos ML, et al. Increased cannabinoid CB1 receptor binding and activation of GTP-binding proteins in the basal ganglia of patients with Parkinson's syndrome and of MPTP-treated marmosets. Eur J Neurosci 2001;14:1827-1832.
16. Brotchie JM. CB(1) cannabinoid receptor signalling in Parkinson's disease. Curr Opin Pharmacol 2003;3:54-61.
17. Brotchie JM, Fox SH, Henry B, et al. The cannabinoid receptor antagonist SR 141716A reduces L-dopa-induced dyskinesia in the MPTP-treated primate model of Parkinson's disease. Br J Pharmacol 1997;123:67.
18. Brotchie JM. Adjuncts to dopamine replacement: a pragmatic approach to reducing the problem of dyskinesia in Parkinson's disease. Mov Disord 1998;13:871-876.
19. Fox SH, Henry B, Hill M, Crossman A, Brotchie J. Stimulation of cannabinoid receptors reduces levodopa-induced dyskinesia in the MPTP-lesioned nonhuman primate model of Parkinson's disease. Mov Disord 2002;17:1180-1187.
20. Sieradzan KA, Fox SH, Hill M, Dick JP, Crossman AR, Brotchie JM. Cannabinoids reduce levodopa-induced dyskinesia in Parkinson's disease: a pilot study. Neurology 2001;57:2108-2111.
21. Frankel JP, Hughes A, Lees AJ, Stern GM. Marijuana for parkinsonian tremor. J Neurol Neurosurg Psychiatry 1990;53:436.
22. Sanudo-Pena MC, Romero J, Seale GE, Fernandez-Ruiz JJ, Walker JM. Activational role of cannabinoids on movement. Eur J Pharmacol 2000;391:269-274.
23. Zhuang S, Kittler J, Grigorenko EV, et al. Effects of long-term exposure to δ9-THC on expression of cannabinoid receptor (CB1) mRNA in different rat brain regions. Brain Res Mol Brain Res 1998;62:141-149.
24. Romero J, Garcia L, Fernandez-Ruiz JJ, Cebeira M, Ramos JA. Changes in rat brain cannabinoid binding sites after acute or chronic exposure to their endogenous agonist, anandamide, or to δ-9-tetrhydrocannabinol. Pharmacol Biochem Behav 1995;51:731-737.
25. Rubino T, Vigano D, Massi P, et al. Chronic δ-9-tetrahydrocannabinol treatment increases cAMP levels and cAMP dependent protein kinase activity in some rat brain regions. Neuropharmacology 2000;39:1331-1336.
26. Sim LJ, Hampson RE, Deadwyler SA, Childers SR. Effects of chronic treatment with δ9-tetrhydrocannabinol on cannabinoid-stimulated [35S]GTPgammaS autoradiography in rat brain. J Neurosci 1996;16:8057-8066.
27. Formukong EA, Evans AT, Evans FJ. Inhibition of the cataleptic effect of tetrahydrocannabinol by other constituents of Cannabis sativa L. J Pharm Pharmacol 1988;40:132-134.
28. Bornheim LM, Kim KY, Li J, Perotti BY, Benet LZ. Effect of cannabidiol pretreatment on the kinetics of tetrahydrocannabinol metabolites in mouse brain. Drug Metab Dispos 1995;23:825-831.
29. Bisogno T, Hanus L, De Petrocellis L, et al. Molecular targets for cannabidiol and its synthetic analogues: effect on vanilloid VR1 receptors and on the cellular uptake and enzymatic hydrolysis of anandamide. Br J Pharmacol 2001;134:845-852.
30. Hampson AJ, Grimaldi M, Axelrod J, Wink D. Cannabidiol and (-)δ-9-tetrahydrocannabinol are neuroprotective antioxidants. Proc Natl Acad Sci U S A 1998;95:8268-8273.
31. Mechoulam R, Panikashvili D, Shohami E. Cannabinoids and brain injury: therapeutic implications. Trends Mol Med 2002;8: 58-61.
32. Hampson AJ, Grimaldi M. Cannabinoid receptor activation and elevated cyclic AMP reduce glutamate neurotoxicity. Eur J Neurosci 2001;13:1529-1536.